Aequus Pharmaceuticals Inc (AQS.V)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of CA$10,000 in Aequus Pharmaceuticals Inc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Aequus Pharmaceuticals Inc (AQS.V) has returned 0.00% so far this year and 0.00% over the past 12 months. Over the last ten years, AQS.V has returned -37.03% per year, falling short of the S&P 500 Index benchmark, which averaged 12.91% annually.

Based on dividend-adjusted daily data since Mar 18, 2015, AQS.V's average daily return is +0.29%, while the average monthly return is -1.87%.

Historically, 30% of months were positive and 70% were negative. The best month was May 2024 with a return of +66.7%, while the worst month was Jan 2025 at -50.0%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 5 months.

On a daily basis, AQS.V closed higher 23% of trading days. The best single day was Mar 7, 2024 with a return of +100.0%, while the worst single day was Nov 12, 2024 at -66.7%.

Aequus Pharmaceuticals Inc has an annualized alpha of 105.19%, beta of 0.17, and R² of 0.00 versus S&P 500 Index. Calculated based on daily prices since March 19, 2015.

• This stock participated in 126.07% of S&P 500 Index downside but only -74.01% of its upside — more exposed to losses than it benefited from rallies.
• Beta of 0.17 may look defensive, but with R² of 0.00 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R² of 0.00 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

AQS.V ranks 51 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The table below present risk-adjusted performance metrics for Aequus Pharmaceuticals Inc (AQS.V) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Aequus Pharmaceuticals Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Aequus Pharmaceuticals Inc was 99.35%, occurring on Nov 12, 2024. The portfolio has not yet recovered.

The current Aequus Pharmaceuticals Inc drawdown is 99.35%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Aequus Pharmaceuticals Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Aequus Pharmaceuticals Inc is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.